Printer Friendly

European Commission Approves Endoceutics' Drug IntrarosaTM for the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women.

Quebec, Canada, January 15, 2018 --(PR.com)-- The European Commission has adopted the following on 8 January 2018: Adoption of Commission Implementing Decision granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Intrarosa - Prasterone," a medicinal product for human use. IntrarosaTM is intended for the treatment of vulvar and vaginal atrophy in postmenopausal women.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages.

IntrarosaTM will be available as a 6.5 mg pessary. The active substance of IntrarosaTM is prasterone, also known as dehydroepiandrosterone (DHEA), a precursor steroid which is converted into oestrogens and androgens. The medicine increases the number of superficial and intermediate cells and decreases the number of parabasal cells in the vaginal mucosa via an oestrogen-mediated mechanism. In addition, it decreases the vaginal pH towards the normal range, thus facilitating the growth of the normal bacterial flora.

The benefit with IntrarosaTM is its ability to improve dyspareunia. The most common side effect is vaginal discharge.

About Endoceutics

Endoceutics is a private pharmaceutical company operating in the field of women's health and hormone-sensitive cancer prevention and treatment. Following approval by the US FDA of Intrarosa[TM] on November 17th 2016, for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause, Endoceutics focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, , including hot flushes, osteoporosis and muscle loss. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates. Endoceutics has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products.

Contact for Endoceutics

Website: www.endoceutics.com

Email: info@endoceutics.com

Phone: (418) 653-0033

Contact Information:

Endoceutics

Fernand Labrie

418-653-0033

Contact via Email

www.endoceutics.com

Read the full story here: https://www.pr.com/press-release/741517

COPYRIGHT 2018 PR.com
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR.com (Press Releases)
Date:Jan 15, 2018
Words:356
Previous Article:Acnodes' 2U Rackmount Computer Comes with Full-size Expansion Slots, Core i CPU, and, 17" Short Depth Chassis..
Next Article:U Recover to Join Sto-Rox First Opioid Crisis Summit.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters